The new drug of Xianyou Pharmaceutical reached 500 million US dollars overseas authorization transactions to set the highest record in the field of self -exemption

According to the terms of the agreement, Xianyou Pharmaceutical will collect 15 million US dollars of down payment of Almirall, and the possible results based on the possible results of multiple indications will be charged up to $ 492 million in development and commercial milestones (including some sales milestones); Hundreds of points in the protocol area of ​​sales are made of levels. It is worth noting that according to public data, the total amount of the agreement set the highest record in the current domestic autoimmune clinical project.

A press release provided by Xianmin Pharmaceuticals shows that the SIM0278 authorized overseas is a highly activated TREG preference IL-2 fusion protein developed by the ancestral pharmaceutical technology platform (IL-2 MU FC) has an important impact on immune T cell proliferation and activation, and it is also one of the popular targets in the world's new drug development field. As a kind of undercut injection innovative drugs that are about to enter the IND, it has the potential to treat a variety of autoimmune diseases, such as systemic lupus erythematosus and special dermatitis.

According to Pharmaceutical Cube data, from January to September 2022, domestic biomedical companies reached 25 License Out transactions, of which nearly 90 % of the transactions were concentrated in the tumor field products. The License Out transactions that have been watched in the industry have previously attracted much attention from the industry, including BTK products cooperated with Biogen and Biogen in 2021, 2018 Hengrui and TG therapeutics, etc., plus the first priority and European old pharmaceutical company Almirall, the old European pharmaceutical company Almirall In the past five years, this record of trading can be described as "rare". This field still has a high threshold for innovation for the domestic pharmaceutical industry.

At present, there is no such engineering IL-2 self-exemptation of disease treatment drugs in the world, but internationally well-known companies such as Anjin, Merckon (acquired by the acquisition of Pandion), Albervi (cooperation with CUGENE) have deployed IL- 2 Self-exemptions for mutant fusion proteins are in the clinical phase 1-2, respectively. However, the Sim0278 of Xianyou Pharmaceutical has no public publishing data. Previously, Tang Renhong, executive director and joint CEO of Xianyou Pharmaceuticals, revealed on the company's enterprise research and development day that the pre-clinical data of the project shows similar best types (BEST- In-Class potential is a key project for the company's plan to carry out global development.

In the capital market, the announcement of the overseas authorization transaction has slightly boosted the company's stock price. As of the afternoon closing, Xianyin Pharmaceutical rose 2.83%.

Daily Economic News

- END -